Replies to post #191964 on Amarin Corp Plc (AMRN)

[biotech_researcher]

As I always thought, there will be others in this space..

[rosemountbomber]

Why haven't they done anything with their drug for this indication for so long? Years of just using the story that it raises blood levels of EPA more than V but they don't seem to want to advance the drug.

[massulo52]

What phase are they in

[Sam81]

bio

Matinas BioPharma (NYSEMKT:MTNB) is up 4% premarket on increased volume on the heels of a Buy rating and $5 (434% upside) price target at BTIG Research citing the potential of next-gen omega-3 fatty acid compound MAT9001 that Matinas says is superior to Amarin's (NASDAQ:AMRN) Vascepa (icosapent ethyl) in lowering high triglycerides.

Might be true or not, need to wait till the completion of their study.
My take is that they are pumping their stock and using AMRN success.
What we, the board know, and soon the medical community will reach eventually is that the success of V in reducing cardiovascular events is not mainly due to reducing TG. Reducing TG is minimal
Having said that, just pumping the stock that MAT9001 is superior to V in reducing TG does not mean reducing cardiovascular events and V is playing in another league that Matina, a way bigger and superior league.

Just my Opinion

[Shawzzzzzz]

All Noise, they are at 8-12 years out.

[dukesking]

BTR. Why do you say this is bearish for AMRN. The 5 cent increase just puts them back where they were last week and the so called premarket pop is based on news of a collaboration for anti-viral drugs. how does that relate to AMRN or Vascepa? I own MTNB but don't see the connection you're making. their Trig lowering drug is no threat to AMRN anytime soon, if ever. IMO

[ggwpq]

The MTNB piggyback on R-I success story has been around for a while and you just decided to light up AMRN now. Are you really a biotech researcher?

[couldbebetter]

That's BS!!! This has been mentioned time and time again.
They have no CVOT! They are in no way a threat to AMRN.